HC Wainwright & Co. Maintains Buy on Eledon Pharma, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a 'Buy' rating on Eledon Pharma (NASDAQ:ELDN) but has lowered the price target from $25 to $13.

October 24, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eledon Pharma's price target has been lowered from $25 to $13 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100